Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Syncona (SYNC) Share News

Syncona's Beacon Therapeutics receives positive data for XLRP therapy

7th May 2025 11:02

(Alliance News) - Syncona Ltd on Wednesday noted its investee Beacon Therapeutics Holdings Ltd received positive data from its trial of laru-zova for the treatment of patients with X-linked retinitis pigmentosa. Read More

Syncona sees negative nine-month return despite quarterly rise

6th Feb 2025 11:19

(Alliance News) - Syncona Ltd on Thursday reported a negative net asset value total return for the financial year to date, despite NAV rising during its third quarter. Read More

Syncona investee Achilles plans liquidation and capital return

5th Feb 2025 11:28

(Alliance News) - Syncona Ltd on Wednesday said portfolio company Achilles Therapeutics PLC is planning to return capital to shareholders though a members' solvent voluntary liquidation. Read More

LONDON MARKET MIDDAY: Stocks red ahead of US trade balance read

27th Dec 2024 12:11

(Alliance News) - Stock prices in London were mostly lower at midday on Friday as market participants continue digesting US jobless data and unrest in Mozambique puts miners on edge. Read More

Syncona investee sells assets to AstraZeneca for USD12 million

27th Dec 2024 09:11

(Alliance News) - Syncona Ltd on Friday said one of its investments Achilles Therapeutics PLC has sold its technology assets to AstraZeneca PLC for USD12 million. Read More

LONDON BRIEFING: Stocks seen down as holiday sales stabilise

27th Dec 2024 07:59

(Alliance News) - The FTSE 100 index in London was called slightly lower on Friday, as investors digest holiday-season sales results in the US and UK. Read More

Syncona hails positive trial data for new Beacon Therapeutics drug

6th Dec 2024 14:55

(Alliance News) - Syncona Ltd on Friday reported promising trial results for the drug laru-zova, the lead asset of Syncona subsidiary Beacon Therapeutics Holdings Ltd. Read More

Syncona net assets values down; announces new portfolio firm Slingshot

14th Nov 2024 12:28

(Alliance News) - Syncona Ltd on Thursday said it launched a new portfolio company as it reported a fall in net asset value, citing a weaker US dollar. Read More

Syncona's Autolus wins FDA approval for aggressive leukaemia therapy

11th Nov 2024 10:28

(Alliance News) - Syncona Ltd announced on Monday that the US Food & Drug Administration has granted marketing approval to one of its portfolio companies for a new product. Read More

UK earnings, trading statements calendar - next 7 days

7th Nov 2024 16:23

Syncona celebrates investee's positive trial data on Gaucher disease

23rd Oct 2024 09:37

(Alliance News) - Syncona Ltd on Wednesday noted positive trial results for a portfolio company's gene therapy aimed at treating people with Gaucher's disease. Read More

TRADING UPDATES: Strix lauds "milestone"; Quartix to meet expectations

15th Oct 2024 15:33

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

Syncona makes further investment in Purespring Therapeutics

9th Oct 2024 08:56

(Alliance News) - Syncona Ltd on Wednesday announced it has committed GBP19.9 million in a series B financing of Purespring Therapeutics, which will be used to advance kidney treatments. Read More

Syncona makes further investment in Resolution Therapeutics

3rd Oct 2024 11:48

(Alliance News) - Syncona Ltd on Thursday said it has committed GBP63.5 million in a series B financing of Resolution Therapeutics, which will be put towards clinical development of a liver disease treatment. Read More

Syncona's Beacon Therapeutics presents trial results at conference

20th Sep 2024 10:58

(Alliance News) - Syncona Ltd on Friday said that its portfolio company, Beacon Therapeutics Holdings Ltd, has presented data at a conference in Barcelona. Read More

Syncona notes investee Achilles' plan to close its lead program

19th Sep 2024 14:11

(Alliance News) - Syncona Ltd on Thursday announced that Achilles Therapeutics will discontinue its lead TIL-based cNeT program, close its Phase I/IIa CHIRON and THETIS clinical trials and explore strategies for maximising potential value from its remaining assets. Read More

FTSE 100 Latest

Value8,554.80

Change23.19